Pimasertib
As of the edition of 20 October 2026, Pimasertib is a small molecule: stopped in 2023; acts on MAP2K1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 14, 5 stopped early
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Blood and lymph; Lungs and airways; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Pimasertib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 6 | 0 | 2 |
| Phase 2 | 6 | 3 | 0 | 3 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2007 to now |
| Sanofi | Lead sponsor of trials | 2011 to now |